Abrocitinib for Refractory Livedoid Vasculopathy: A Case Report and Narrative Literature Review.
- 1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
- 2Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Abstract
Livedoid vasculopathy (LV) is a rare, chronic, pauci-inflammatory thrombo-occlusive microangiopathy of the dermal venules characterized by recurrent painful ulcers, livedo racemosa, purpura, and atrophie blanche. Conventional anticoagulant and antiplatelet therapy is frequently insufficient, and refractory disease remains a therapeutic challenge. We report a 48-year-old man with a 2-year history of painful, reticulated purpuric ulcers over the bilateral malleoli, histopathologically consistent with LV, who had failed sequential therapy with systemic corticosteroids, rivaroxaban, and compound rutin. Off-label treatment with abrocitinib 100 mg once daily was started as monotherapy, pain and exudation improved within 4 weeks, and by week 12 all ulcers had re-epithelialized, ankle edema and reticulated erythema had resolved, and inflammatory markers had normalized, without adverse events. The dose was tapered from month 3 and discontinued at month 6, and the patient remained free of recurrence during the 2-month post-discontinuation follow-up. A narrative literature search identified 18 reports and case series that together describe approximately 29 patients with LV treated with Janus kinase (JAK) inhibitors (baricitinib, tofacitinib, upadacitinib, or abrocitinib), most of whom improved. This hypothesis-generating observation is compatible with a therapeutic effect of abrocitinib in refractory LV, and it supports prospective evaluation of JAK inhibition in this disabling condition.
Related
- Symptomatic Calcaneal Intraosseous Lipoma Mimicking Refractory Heel Pain: A Case Report and Review of the Literature
- Reversal of refractory epilepsy in an adult with GAMT deficiency: A case report and comparative literature review
- Staged surgical management of an acute angle-closure crisis with medically refractory intraocular pressure elevation : A case report and literature review
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case
- External Lumbar Drainage for Refractory Intracranial Hypertension in Acute Brain Injury: A Narrative Review and Case Series
BibTeX
@article{wang2026abrocitinib,
title = {{Abrocitinib for Refractory Livedoid Vasculopathy: A Case Report and Narrative Literature Review.}},
author = {Xuchao Wang and Qinglin Liu and Shangshang Wang},
journal = {Clinical, cosmetic and investigational dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s652242},
url = {https://europepmc.org/article/MED/42953103},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Abrocitinib for Refractory Livedoid Vasculopathy: A Case Report and Narrative Literature Review.
AU - Xuchao Wang
AU - Qinglin Liu
AU - Shangshang Wang
PY - 2026
DA - 2026/10/23
JO - Clinical, cosmetic and investigational dermatology
DO - 10.2147/ccid.s652242
UR - https://europepmc.org/article/MED/42953103
AB - Livedoid vasculopathy (LV) is a rare, chronic, pauci-inflammatory thrombo-occlusive microangiopathy of the dermal venules characterized by recurrent painful ulcers, livedo racemosa, purpura, and atrophie blanche. Conventional anticoagulant and antiplatelet therapy is frequently insufficient, and refractory disease remains a therapeutic challenge. We report a 48-year-old man with a 2-year history of painful, reticulated purpuric ulcers over the bilateral malleoli, histopathologically consistent with LV, who had failed sequential therapy with systemic corticosteroids, rivaroxaban, and compound rutin. Off-label treatment with abrocitinib 100 mg once daily was started as monotherapy, pain and exudation improved within 4 weeks, and by week 12 all ulcers had re-epithelialized, ankle edema and reticulated erythema had resolved, and inflammatory markers had normalized, without adverse events. The dose was tapered from month 3 and discontinued at month 6, and the patient remained free of recurrence during the 2-month post-discontinuation follow-up. A narrative literature search identified 18 reports and case series that together describe approximately 29 patients with LV treated with Janus kinase (JAK) inhibitors (baricitinib, tofacitinib, upadacitinib, or abrocitinib), most of whom improved. This hypothesis-generating observation is compatible with a therapeutic effect of abrocitinib in refractory LV, and it supports prospective evaluation of JAK inhibition in this disabling condition.
SN - 1178-7015
ER -